Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 12Other hematologic neoplasm 5Lymphoid 4Gastrointestinal 4Dermatologic 4Plasma cell 3Myeloid 2Tumor-Agnostic 1Thoracic 1Other 1Head & Neck 1Gynecologic 1Genitourinary 1Classical hematology 1CNS 1

Conditions

Multiple Myeloma 3Renal Insufficiency 1Recurrence 1

Interventions

Dexamethasone 373Lenalidomide 206Bortezomib 200Cyclophosphamide 178Melphalan 135Calcium Dobesilate 120daratumumab 107pomalidomide 74carfilzomib 74fludarabine phosphate 71Peripheral Blood Stem Cell Transplantation 66Thalidomide 57Filgrastim 57Mycophenolic Acid 56Busulfan 55Tacrolimus 48Granulocyte Colony-Stimulating Factor 47ixazomib 45fludarabine 45Whole-Body Irradiation 44dexamethasone acetate 36Cyclosporine 35isatuximab 34Etoposide 34Antilymphocyte Serum 32dexamethasone 21-phosphate 30elotuzumab 28auricularum 27Prednisone 27plerixafor 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Tablets × Plasma cell × Clear all
NCT04717700 2025-03-18

SABLe

Odense University Hospital

Phase 2 Active not recruiting
50 enrolled
Plasma cell

Multiple Myeloma

NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Celgene

Phase 2 Completed
81 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT02756663 2016-11-08

PANORAMA-5

Novartis

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡